User:Mr. Ibrahem/Trametinib
 | |
| Clinical data | |
|---|---|
| Trade names | Mekinist |
| Other names | GSK1120212, trametinib dimethyl sulfoxide (DMSO) |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a613040 |
| License data | |
| Routes of administration | By mouth[1] |
| Drug class | MEK inhibitor[2] |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C26H23FIN5O4 |
| Molar mass | 615.404 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Trametinib, sold under the trade name Mekinist, is a medication used to treat certain types of melanoma, non-small cell lung cancer, and anaplastic thyroid cancer.[1][3] Specifically it is used for cancers with the BRAF V600E mutation.[1] It is taken by mouth.[1]
Common side effects include rash, diarrhea, tiredness, swelling, nausea, and fever.[1] Other side effects may include new cancers, bleeding, colitis, blood clots, and heart failure.[3] Use during pregnancy may harm the baby.[3] It is a MEK inhibitor and blocks both MEK1 and MEK2.[2]
Trametinib was approved for medical use in the United States in 2013 and Europe in 2014.[3][1] In the United Kingdom a month of medication costs the NHS about £4,800 as of 2021.[4] This amount in the United States costs about 13,200 USD.[5]
References[edit]
- ^ a b c d e f g h i "Mekinist". Archived from the original on 9 August 2021. Retrieved 8 October 2021.
- ^ a b "Trametinib". NCI Drug Dictionary. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Archived from the original on 2015-05-11. Retrieved 2021-07-21.
- ^ a b c d e "Trametinib Dimethyl Sulfoxide Monograph for Professionals". Drugs.com. Archived from the original on 11 April 2020. Retrieved 8 October 2021.
- ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1060. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ "Mekinist Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 11 April 2021. Retrieved 8 October 2021.